CPA
PCRX icon

Capital Performance Advisors’s Pacira BioSciences PCRX Stock Holding History

Capital Performance Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-557
Closed -$8.38K – 1941
2024
Q3 		$8.38K Buy
+557
New +$9.52K ﹤0.01% 909

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Capital Performance Advisors's PCRX Position: Q4 2024 in Review

Capital Performance Advisors sold out of Pacira BioSciences (PCRX) in Q4 2024, closing a stake of 557 shares — an estimated $8.38K sold.

Capital Performance Advisors first reported a position in PCRX in Q3 2024 and held it in 1 quarter. The position peaked at $8.38K in Q3 2024. 233 funds tracked by Wall St. Rank hold PCRX as of Q4 2024.

  • Capital Performance Advisors reported no remaining Pacira BioSciences position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 557 Pacira BioSciences shares in Q4 2024, an estimated $8.38K.
  • Capital Performance Advisors first reported a position in Pacira BioSciences in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Pacira BioSciences position peaked at $8.38K in Q3 2024.
  • 233 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.